The following is a review of the role of PF-4 and CTAP-III in inhibition and regulation of tumor angiogenesis, respectively; results from rPF-4 clinical trial; and PF-4 and CTAP-III as cancer biomarkers. This evidence concerns the gene PF4 and cancer.